facilitates adherence to intensive insulin therapy regimens, helps to improve lifestyle flexibility and reduces injection pain compared with conventional syringe-based regimens. Together these ...
Adjusted EBITDA margin increased to 37.2% from 25.2% in Q4 2024, driven by cost reductions and operational improvements. Management's tone shifted positively, highlighting stronger-than-expected ...
72 hr Manufacturer Insulin as part (rDNA origin) injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi ...
Q1 2025 Earnings Call Transcript February 6, 2025 Embecta Corp. beats earnings expectations. Reported EPS is $0.65, ...
Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024. "Building on our ...
Guj Inject Kera Standalone June 2024 Net Sales at Rs 3.05 crore, up 1881.39% Y-o-Y Aug 13 2024 01:37 PM Guj Inject Kera Standalone December 2023 Net Sales at Rs 0.22 crore, up 115.04% Y-o-Y Feb 14 ...
Molecular communications in the bloodstream is a promising area of research, since the bloodstream has the ability to ...
The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...
The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback